Quantitative Archives - TBC repository

Home
/
Projects

Quantitative

Willingness to receive a future adult tuberculosis vaccine in Lusaka, Zambia: Perspectives from community members and healthcare workers

One or more new adult TB vaccines could become available in the next 5-7 years. To assess willingness to receive a new TB vaccine, we conducted a household- and facility-based survey among adult community members and healthcare workers (HCWs), respectively, in Lusaka, Zambia

IGRA prevalence study

2024-2025

Planned

A cross-sectional study to determine IGRA positivity rate to assess eligibility for participation in tuberculosis (TB) vaccine efficacy trials

TB vaccine advocacy and acceptance in South Africa

2024

Completed

Gathering a range of perspectives to provide early-stage insights into TB vaccine advocacy and acceptance in South Africa

Insights into TB vaccine acceptability among adolescents in Khayelitsha through community engagement

Ongoing

Initially designed as an internal assessment of the impact of engagement workshops, we used short surveys to understand high-school learner perspectives of vaccines, focusing on COVID 19, TB and HIV vaccines. Between 2022 and 2024, we collected responses from 350 adolescents (14-18 years old). All participants live in Khayelitsha, where high rates of TB (4224 cases notified in the last year) intersect with socio-economic challenges

New tuberculosis vaccines are in late-stage trials, but how confident is the public in high burden countries in vaccines?

Ongoing

With tuberculosis (TB) vaccine candidates in late-stage trials, it is important to prepare for implementation to avoid delays upon licensure. General confidence in vaccines has been identified as an anticipated barrier to introducing new TB vaccines. In the absence of detailed TB specific vaccine acceptability and confidence data, we analysed currently available vaccine confidence data in countries appearing on one of the World Health Organization (WHO) high burden lists to investigate vaccine confidence in countries with a high TB burden

Epidemiologic study to assess the IGRA positivity in populations with a high TB

2021 - 2024

M72/AS01e

Ongoing

Tuberculosis (TB) vaccine efficacy trials evaluating prevention of disease must be feasible in size and duration and would ideally take place at clinical trial sites that enroll from communities with the highest incidence rates. In preparation for the Phase 3 trial of the investigational M72/AS01E-4 vaccine, we conducted a multi-country study, using interferon gamma release assay (IGRA) positivity as a proxy for expected incidence of TB. In addition to the above objects, the results from this study could help in in new vaccine introduction to identfy TB hotspot areas.

Formative work to understand factors affecting future TB vaccines acceptance and readiness

2023-2027

Hypothetical vaccines

Ongoing

This project aims to collect data to: 1) Assess health facility and health systems readiness for a new TB vaccine, and 2) Explore decision-making factors for new TB vaccine demand and acceptance

ACEITar: Evaluation of the acceptability of new and repurposed tuberculosis vaccines in Mozambique

2022-2024

BCG revaccination, Hypothetical vaccines

Ongoing

This is a mixed-methods study collecting information on willingness to receive a new TB vaccine among adolescents, their caretakers, and adults in Mozambique, a high TB burden country, to assess potential barriers to high uptake of new TB vaccines.

Country and target population prioritization

2023-2024

Hypothetical vaccines

Ongoing

Evidence-based matrixing approach to identify priority countries and target populations through an iterative process, engaging a set of diverse stakeholders

What do people want?

2024

Hypothetical vaccines

Planned

Investigate current TB prevention modalities vs vaccine. We lack understanding of preferences and trade offs people would be willing to make across a spectrum of issues related to study design, type of vaccines, how they are given, how often, where they are given, to whom, efficacy estimates and side effects etc.